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Background and Aims 
The gastric premalignant conditions (GPCs) diagnosis rely on endoscopy with 
mucosal sampling. We hypothesized that the endoscopists’ biopsy rate (EBR) might 
constitute a quality indicator for esophagogastroduodenoscopy (EGD) and we have 
analyzed its association with GPC detection and the rate of missed gastric cancers 
(GCs). 
Methods 
We analyzed EGD databases from 2 high-volume outpatient units. EBR values, 
defined as proportion of EGDs with ≥1 biopsy to all examinations, were calculated for 
each endoscopist in Unit A (derivation cohort) and divided by the quartile values into 
4 groups. GPC detection was calculated for each group and compared using 
multivariate clustered logistic regression models. Unit B database was used for 
validation. All patients were followed with Cancer Registry for missed GCs, 
diagnosed between 1 month and 3 years after negative EGDs. 
Results 
Sixteen endoscopists in Unit A performed 17,490 EGDs of which 15,340 (87.7%) 
were analyzed. EBR quartile values were 22.4% to 36.7% (low EBR), 36.8% to 
43.7% (moderate), 43.8% to 51.6% (high), and 51.7% and 65.8% (very-high); median 
value 43.8%. The moderate, high, and very high EBR groups’ odds ratios of 
detecting GPC were 1.6 (95% CI, 1.3-1.9), 2.0 (95% CI, 1.7-2.4) and 2.5 (95% CI, 
2.1-2.9), respectively, when compared with low EBR group (P<.001). This 















Endoscopists with higher EBR (≥43.8%) had a lower risk of missed cancer as 
compared with lower EBR group (OR=0.44; 95% CI, 0.20-1.00; P=.049). 
Conclusions 
The EBR parameter is highly variable among endoscopists, associated with efficacy 
in GPC detection and the rate of missed GCs.  
Keywords: Gastroscopy; Quality Indicators; Precancerous Conditions 
 
INTRODUCTION 
Gastric cancer (GC) usually presents at an advanced stage in the Western 
world with limited curative therapy opportunities. Despite a consistent decline in the 
global incidence and mortality of GC, it remains to be the fifth most common 
malignancy in the world and the third leading cause of cancer mortality (1). In 2015, 
there were 1.3 million incident cases and 819,000 deaths due to GC worldwide (2).  
A significant proportion of these neoplasms arises from benign, precancerous 
conditions. For instance, the most common subtype of gastric cancer, a non-cardia 
intestinal-type adenocarcinoma, develops on a background of longstanding mucosal 
inflammation through a number of stages from chronic atrophic gastritis, by way of 
intestinal metaplasia, through low-grade and high-grade dysplasia, up to cancer. This 
sequence is known as Correa’s cascade (3).  
Esophagogastroduodenoscopy (EGD) with biopsies has a primary role in the 
diagnosis and surveillance of patients with gastric precancerous conditions (GPCs) 















However, despite growing experience in the field of endoscopy, a significant 
proportion of neoplastic lesions remain undetected. A recent meta-analysis has 
shown that 11.3% of upper gastrointestinal tract (UGI) cancers are missed at EGD up 
to 3 years before the diagnosis (4). These findings underscore the importance of 
quality control for this procedure. 
In recent years, several guidelines and position statement papers on EGD 
quality have been published (5-7). Most of the presented measures, however, are 
based on low-quality evidence and are not associated with significant outcomes, 
such as neoplasia detection or interval cancer risk. Because the diagnosis of 
precancerous conditions and early cancers in conventional EGD relies on biopsy 
sampling of suspicious areas in the UGI tract we hypothesized that within a group of 
competent endoscopists the rate of obtaining biopsy specimens during endoscopy 
broadly reflects the number of detected abnormalities. We considered this as a 
potentially objective and reproducible quality marker for routine, outpatient EGD. 
Therefore, the aim of this study was to investigate the variability in taking biopsies by 
endoscopists and to analyze the association between a novel quality indicator, the 
endoscopists’ biopsy rate (EBR), and detection of GPCs in the stomach and the rate 
of missed GCs.  
METHODS 
Study design 
This was a multicenter, retrospective, cohort study analyzing outpatient EGD 
databases and histopathology reports from 2 high-volume, distinct geographically, 















• Unit A – Endoscopy unit at the Department of Cancer Prevention, the Maria 
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 
Warsaw.  
• Unit B – Endoscopy unit by the Department of Gastroenterology, Pomeranian 
Medical University, Szczecin. 
The database from Unit A was used as a derivation cohort to assess the EBR 
parameter and to analyze its correlation with GPC detection. Unit B database was 
used for external validation. Finally, both databases were used to find an association 
between EBR and the rate of missed cancers (detailed methodology explained 
below). The research proposal was reviewed and accepted by the ethics committee 
at the authors’ institution on June 14, 2017 (49/PB/2017).  
Endoscopists’ biopsy rate (EBR) parameter 
For each endoscopist, we counted biopsy rate (EBR) as a percentage of 
EGDs with at least one biopsy specimen obtained for histology from the esophagus, 
stomach, or the duodenum (ICD-9 codes 45.14, 45.16, 42.24) to all performed EGDs 
in the study period. Biopsies for rapid urease test were not included.  
Derivation group (Unit A)  
In the analysis, we have included full reports on subsequent adult patients 
undergoing diagnostic EGD, mostly for UGI symptoms evaluation. All endoscopists 
included in the study were staff specialists in internal medicine or gastroenterology, 
who underwent dedicated training in UGI endoscopy and were considered competent 
to perform diagnostic EGDs independently. Reports on juvenile patients (<18 years 















and endoscopists who did fewer than 100 procedures during the study period. Unit A 
database consisted of endoscopy reports including: 
• Patients’ data: personal identification number (PESEL), hospital number (PID), 
gender and date of birth.  
• EGD data: indication, date, type of sedation, type (model) of the endoscope, 
examination report (descriptive), main gastroscopy findings, procedure ICD-9 
code, number and description of containers used for histopathology 
specimens, and rapid urease test (if obtained).  
• Endoscopist data: full name of endoscopist performing the procedure and 
assisting physician (if present). 
All indications for EGD were coded and assigned into 4 groups: (1) symptoms 
evaluation (1a – benign symptoms 1b- alarm symptoms), (2) premalignant conditions 
surveillance, (3) cancer and nonepithelial neoplasms (known cancer, high suspicion 
of cancer in imaging tests, cancer during treatment, cancer follow-up), and (4) others. 
We linked EGDs with corresponding histopathology reports. Each histopathology 
finding was assigned to the esophagus, stomach, or duodenum and afterward 
characterized as a normal mucosa (no pathology in the microscopic examination), 
non-neoplastic lesions (eg, acute gastritis, fundic gland polyp, etc), precancerous 
condition (eg, atrophic gastritis, intestinal metaplasia, etc), cancer, or non-epithelial 
neoplasm (eg, neuroendocrine tumors, GISTs, lymphomas etc). 
For each endoscopist we counted EBR values and then divided them by the 
quartile values into 4 groups, corresponding to low, moderate, high, and very-high 
EBR groups. We analyzed the association between EBR groups and detection of 















high-grade), and additionally detection of all UGI premalignant conditions including 
GPCs, but also Barrett’s esophagus (BE), squamous intraepithelial neoplasm (SIN), 
and duodenal adenomas (DAs).  
Validation group (Unit B)  
The Unit B database constituted the validation cohort. For this database, we 
have used the same inclusion and exclusion criteria as for derivation cohort and 
coded endoscopy reports and histopathology findings in a similar fashion. This 
database, however, did not contain information on indications for EGD, type of the 
endoscope and sedation.  
Missed cancers 
We followed-up all patients from Unit A and Unit B using their personal 
identification numbers (PESEL) through the National Cancer Registry to identify 
those diagnosed with GC coded C.16 according to the International Classification of 
Diseases, 10th Revision – ICD 10 before the December 31, 2015. Missed cancers 
were defined as those diagnosed after 1 month and within 3 years after an EGD 
showing no evidence of cancer. We have used the same criteria for missed GCs as 
in several previous studies within the field (4,8-11). This definition is based on 
observatory studies by Fujita et al, (12) showing that a doubling time of gastric 
cancer on the mucosal surface is approximately 2 to 3 years. Therefore, an 
assumption is made, that cancers diagnosed within 3 years after negative 
gastroscopy were already present at the time of initial examination as either early 
malignancy or precursor lesion. Cancers diagnosed at the initial EGD (and within 1 















all cases of delayed histopathology results), and those diagnosed after 3 years were 
classified as latent cancers.  
Statistical Methods 
Baseline characteristics were prepared using medians, interquartile ranges, 
and contingency tables. Spearman correlation was used to measure the association 
between EBR and the risk of GPC and dysplasia at EGD. We analyzed the 
association between EBR groups and the detection of GPCs and all UGI 
premalignant conditions using multivariate clustered logistic regression models. 
Because one patient may have had more than one EGD, standard errors of model 
estimates were clustered according to patients to adjust for intrapatient correlation. 
We reported odds ratios (ORs) and 95% confidence intervals (CI) adjusted for 
patient’s sex and age at the time of diagnosis. ll statistical tests were 2-sided. P 
value of less than 0.05 was considered to indicate statistical significance. All 
analyses were performed with Stata software, version 13.1 (Stata Corporation, 
College Station, Tex, USA). 
RESULTS 
Derivation cohort  
Unit A database consisted of 17,490 EGD reports on 13,875 patients, of which 
2,150 (12.3%) met exclusion criteria and the remaining 15,340 (87.7%) were 
analyzed (12,433 patients). The study flowchart is presented in Figure 1. Most 
patients (10,503; 84.5%) had one EGD, 1,365 (11.0%) had 2 EGDs and 565 (4.5%) 
had 3 or more EGDs (maximum 14). In total, 1,331 (12.7%) GPCs were detected, 
including 188 diagnoses of gastric dysplasia (14.2%; any grade), 150 BE (1.0%), 16 















91 years) and the most common indication for EGD was an upper abdominal pain, 
accounting for 4379 procedures (28.5%). Most of the EGDs (n=8,976) were 
performed on female patients (58.5%). Nearly all procedures were performed with 
local anesthetic only (n=15,317, 99.8%) and with the use of standard video-
endoscopes (93.6%). Detailed characteristics of Unit A cohort are presented in Table 
1. 
The EBR value of 16 endoscopists in this cohort varied between 22.4% and 
65.8%. The median EBR value was 43.7% and the quartile values of EBR were as 
follows: 22.4% to 36.7% (low EBR group), 36.8% to 43.7% (moderate EBR group), 
43.8% to 51.6% (high EBR group), and 51.7% to 65.8% (very-high EBR group), 
respectively. Endoscopists were assigned to each group (4 in each group). The 
moderate, high, and very-high EBR groups’ ORs of detecting GPC were 1.6 (95% CI, 
1.3-1.9; P<.001), 2.0 (95% CI, 1.7-2.4; P<.001) and 2.5 (95% CI, 2.1-2.9; P<.001), 
respectively, as compared with low EBR group. We performed additional analysis 
extracting only gastric dysplasia (GD) detection (any grade). For GD, the ORs were 
2.1 (95% CI, 1.1-4.0; P=.024), 2.7 (95% CI, 1.5-4.7; P=.001) and 1.9 (95% CI, 1.1-
3.4; P=.025), for the moderate, high, and very-high EBR group, respectively, when 
compared to low EBR group. Last, for all UGI premalignant conditions, the moderate, 
high, and very-high EBR groups’ ORs were 1.6 (95% CI, 1.3 – 1.9; P<.001), 1.9 (95% 
CI, 1.6 – 2.2; P<.001) and 2.5 (95% CI, 2.1 – 2.9; P<.001), respectively, as compared 
with low EBR group. 
Additionally, having indications for the EGDs, we have performed sensitivity 
analysis in which we have excluded all procedures with indications of previously 
recognized premalignant conditions, genetic cancer syndromes, cancer or high 















(26.8%) and the remaining 12,800 EGDs were analyzed. The association between 
EBR and GPC detection was maintained. The moderate, high and very high EBR 
group ORs for detecting GPC were 1.8 (95% CI, 1.4–2.2; P<.001), 2.2 (95% CI, 1.8–
2.7; P<.001) and 3.2 (95% CI, 2.7–3.8; P<.001) and for GD detection it was 2.3 (95% 
CI, 1.1–4.8; P=.021), 2.8 (95% CI, 1.5–5.2; P=.002) and 2.1 (95% CI, 1.1–3.9; 
P=.026), respectively, as compared with low EBR group.  
Validation cohort  
Unit B database consisted of 14,589 EGD reports on 11,333 patients, of which 
295 (2.0%) met exclusion criteria and the remaining 14,294 (98.0%) were analyzed. 
Most patients (9,425; 83.2%) had one EGD, 1,334 (11.8%) had 2 EGDs, and 574 
(5.1%) had 3 or more EGDs (maximum 14). In total, 285 GPCs were detected, 
including 118 (0.8%) GD (any grade). The median patients’ age was 56 (range 18-
96). As in the derivation cohort, most of the EGDs (n=8,932) were performed on 
females (62.5%).  
The EBR range of 10 endoscopists in Unit B varied between 22.0% and 
52.9%. Using the EBR quartile ranges established in Unit A, we have assigned 
endoscopists from Unit B into 4 EBR groups and analyzed the ORs of GPC 
detection. The moderate, high, and very-high EBR groups’ ORs of detecting GPCs 
were 0.8 (95% CI, 0.5-1.2), 3.0 (95% CI, 2.4-3.7) and 5.6 (95% CI, 3.2-9.8), 
respectively, when compared with low EBR group. For detecting GD, it was 0.9 (95% 
CI, 0.5-1.6), 1.0 (95% CI, 0.6-1.6), and 3.8 (95% CI, 1.3-10.6), when compared with 
low EBR group. EBR values from Unit A and B are presented in Table 2 . 
Overall, for Units A and B combined, the endoscopists’ EBR value was 















trend was seen, however without statistical significance (rho=0.39; P=.057) (Figure 
2). 
EBR and missed gastric cancers  
For this analysis, we have divided all endoscopists by the EBR median value 
into higher (≥43.8%) and lower (<43.8%) EBR group to analyze the association 
between EBR group and the odds of missed cancer during EGD.  
A total of 350 GCs were diagnosed at Unit A and B in the study period. This 
included 288 GCs identified at baseline endoscopy and 62 GCs identified through 
cross-reference with the National Cancer Registry. Of the latter, 36 GCs were 
classified as missed cancers (18 in Unit A and 18 in Unit B; median time from EGD to 
cancer diagnosis: 0.9 years, IQR: 0.4-1.7 years) and 26 as latent cancers (median 
time from EGD to cancer diagnosis: 7.3 years, IQR: 4.6-8.5 years) (Figure 1 ). The 
overall GC miss rate was 10.3%. Twenty-nine of the missed cancers were diagnosed 
among endoscopists with lower EBR (80.6%), and 7 among those with higher EBR 
(19.4%).  
Using a logistic regression model adjusted for patients’ age, gender, and 
endoscopy unit, we have shown that patients examined by endoscopists with higher 
EBR had a 56% lower risk of missed cancer during EGD as compared with lower 
EBR group (OR = 0.44; 95% CI, 0.20-1.00; P=.049). The incidence of missed GC in 
the lower EBR group was 49.6 per 100,000 person-years and in the higher EBR 
group, it was 23.1 per 100,000 person-years. The risk difference was 26.5 per 
100,000 person-years (95%CI 1.7-51.4 per 100,000 person-years).  















For all endoscopists included in the study we have analyzed the rate of negative 
biopsies, defined as a proportion of biopsies showing no abnormality in the 
microscopic assessment among all performed EGDs. This rate varied between 
endoscopists between 3.5% to 41.0%. The low EBR group had the lowest rate of 
negative biopsies (mean 10.8%, range 3.5%-20.5%) when compared with other 
groups because the mean negative biopsy rate for the moderate, high, and very-high 
EBR groups were 20.5% (range 8.8%-30.0%, P=.015), 23.3% (range 5.8%-29.0%, 
P=.007), and 32.2% (range 14.3%-41.0%, P<.001), respectively (Figure 3 ).  
DISCUSSION 
Unlike in the field of colonoscopy, for which multiple quality indicators have 
been identified (13-15), there are very few performance measures for EGD and most 
of them are not validated, based on low-quality data, and rarely associated with 
patient-oriented outcomes. In our study, we have characterized and validated a new 
performance measure, EBR, basing on a hypothesis that the rate of obtaining 
biopsies, similarly to polyp detection rate in colonoscopy, broadly reflects the number 
of abnormalities detected in routine outpatient EGDs. We have found that the biopsy 
rate was markedly variable between endoscopists, and this was observed both in the 
derivation cohort (EBR range 22.4%-65.8%) and the external validation cohort (EBR 
range 22.0%-52.9%). We have shown that the EBR parameter was strongly 
associated with GPCs detection (rho=0.83; P<.001) and, most importantly, with the 
risk of missed GCs. Decision to use these end-points was supported by a fact that 
GC is the most common UGI malignancy in Western countries and the GPC 
detection was previously used in other studies on UGI quality indicators (17). 
Nevertheless, the utility of EBR was also maintained when we have included all UGI 















Recently, several gastroenterology societies have published guidelines and 
statement papers on performance measures for UGI tract endoscopy (5-7). Up to 
date, the most broadly studied parameter for EGD is the procedure time. For 
example, an association between the examination time of BE and the detection rate 
of high-grade dysplasia and adenocarcinoma was shown (16). In a subsequent study 
by Teh JL et al, (17) endoscopists with mean EGD examination time of more than 7 
minutes were more likely to detect precancerous lesions and cancers in the UGI 
tract, as compared to those with shorter examination time. Finally, a most recent 
study by Park JM et al (18) found that endoscopists with a mean examination time of 
more than 3 minutes (withdrawal time after reaching the duodenum and cleaning the 
gastric mucosa), were more likely to detect gastric adenomas and cancers than “fast 
endoscopists.” In this study, in relation to ours, the frequency of endoscopic biopsies 
varied significantly among endoscopists (range 6.9%–27.8%) and was strongly 
correlated with the rate of neoplasm detection (R2 =0.76; P=.015) (18). The biopsy 
rates were notably lower than those in our study (22.0% - 65.8%); however, the 
South Korean study involved asymptomatic screening population, whereas our 
cohort included patients being evaluated for GI symptoms, more often requiring 
biopsy sampling. To compare, in a previous Japanese study on symptomatic 
patients, the mean biopsy rate was 55.0%, which was similar to ours; however, the 
higher rate of GC in Japan and widespread use of advanced imaging techniques is a 
confounder in this comparison (8).  
By cross-linking our data with the National Cancer Registry, we investigated 
the rate of missed GCs. We identified 36 EGDs negative for cancer, in patients who 
were diagnosed with GC between 1 month and 3 years afterward. We have used 















GI cancers (4,8-11). The GC miss rate in our cohort was 10.3%. In comparison, a 
report by Raftopoulos et al (9) has shown a missed cancer rate of 6.7% in a cohort of 
28,000 patients. This number, however, included all UGI cancers (duodenum, 
stomach, and esophagus). When including only GCs, the missed cancer rate was 
4.3%, which is over 2-fold lower than in our study. On the other hand, previous Asian 
studies reported a missed GC rate of 14% and 26% (8,10), which is substantially 
higher than it was shown in our study. These reports, however, originate from 
countries with a high incidence of GCs, with different histological criteria for cancer.   
The EBR parameter was assessed using a large dataset of nearly 30,000 
EGDs performed by 26 endoscopists. The main strength of our study is that it 
includes an external validation in a high-volume, geographically distinct unit. EBR 
parameter is easy to calculate because it only requires the number of EGDs with at 
least one biopsy obtained from any part of the UGI tract (this can be determined by 
ICD-9 coding) and the total number of procedures. In the EBR calculations we 
included EGDs with biopsies obtained from any part of the UGI tract (esophagus, 
stomach, duodenum) to make the EBR calculation as simple as possible. We have 
shown that EBR is associated with the detection of all UGI premalignant conditions, 
however in presenting our results we have focused on gastric findings (GPC 
detection and rate of missed GCs) as a surrogate end-point to objectively compare 
endoscopists’ performance, as was done in previous studies (17). 
Our study was limited by a few relevant factors, and a retrospective design is 
the main one. It needs to be emphasized that the EBR parameter was developed in 
the setting of routine outpatient endoscopy units and is not applicable in inpatient 
setting, where therapeutic procedures constitute a significant proportion of 















can be explained by difference in expertise because Unit A is a endoscopy unit 
based around oncology center and Unit B is based around general gastroenterology 
department. Despite those differences in performance, we could still show a 
meaningful difference in performance between EBR group’s in the validation cohort, 
which proves the reproducibility of this parameter. It must be underlined, that our 
electronic database did not include information on patients’ risk factors, such as 
smoking, medications, body mass index and the use of advanced imaging 
techniques, such as virtual chromoendoscopy. Most of the procedures were 
performed using standard video-resolution endoscopes, which represents the 
standard of care in routine outpatients’ endoscopy practice within the time frames of 
the study. This, on one hand, has the advantage of uniform (hence comparable) 
equipment being used among endoscopists in our study, but on the other hand, it 
does not represent the current shift in standard of care toward high-definition 
endoscopy. Moreover, we did not have the procedure time recorded in our 
databases. This limitation is important because we believe that EBR and procedural 
time might be correlated with each other and both of these parameters represent the 
quality of mucosal inspection during EGD. Lastly, we could not extract the data on 
the distribution and extension of the GPCs. This limitation is particularly important in 
terms of atrophic gastritis, which is associated with significant risk of cancerous 
change when diffused or multifocal, however low risk (not requiring surveillance) 
when only limited to the gastric antrum (19). We also did not have data on whether 
biopsy protocols, such as the Sydney protocol (20), were followed in both units and 
could not differentiate whether biopsies were targeted or random. We are also aware, 
that just like polyp detection rate in colonoscopy, EBR parameter might be 















parameter being monitored may encourage endoscopists to take more random 
biopsies to boost their EBR value without influencing the patients’ outcome. A 
potential solution to this problem could be adjusting the EBR parameter to the rate of 
GPCs diagnosis for each endoscopist. 
The utility of EBR requires further evaluation in prospective trials to determine 
the most accurate range of its value, that would represent the highest diagnostic 
yield, and the lowest cost burden at the same time. Increasing EBR values are 
associated with growing number of negative biopsies, hence costs, and our study 
may suggest that endoscopists within high EBR group (43.8%-51.6%) represent the 
best balance between UGI high-risk lesion detection and missed GC diagnoses and 
the rate of negative biopsies (costs).  
We are aware, however, that the EBR parameter is dependent on the regional 
prevalence of the GPC and GC. Therefore, rather as an absolute value, EBR should 
be used to compare endoscopists within the same unit/region, to see the variation of 
its value, and to identify endoscopists requiring improvement. In our view, EBR is a 
parameter which indirectly informs about the quality of inspection of gastric mucosa 
(like procedure time). Meticulous inspection of the mucosa translates into better 
endoscopic recognition of GPCs, which needs to be confirmed with a biopsy. The 
higher rate of GPCs diagnoses is also of value for the patients, who are then triaged 
to the population of increased GC risk in the future.  
 In conclusion, endoscopists’ biopsy rate (EBR) is highly variable, and we 
believe that within a group of comparably experienced endoscopists it correlates with 
a detection rate of mucosal abnormalities in the upper GI tract during EGD. This is 















diagnostic outpatient EGD and to show its correlation with important, patient-oriented 
outcomes such as GPC detection and the rate of missed GCs.  
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*- atrophic gastritis, intestinal metaplasia and gastric dysplasia 
**- dyspepsia, abdominal pain, reflux,  
***- anaemia, GI bleeding, dysphagia, weight loss, emesis;  
EBR- endoscopists’ biopsy rate; EGD- esophagogastroduodenoscopy; GPC- gastric 
precancerous conditions 









All patients 15,340 (100%) 1,331 (8.7%) 318 (2.1%) 825 (5.4%) 188 (1.2%) 188 (1.2%) 
Age groups (median age = 57 years, range: 18 - 91) 
18 - 49 4,371 (28.5%) 174 (1.1%) 53 (0.3%) 100 (0.7%) 21 (0.1%) 25 (0.2%) 
50 - 69 7,992 (52.0%) 727 (4.7%) 168 (1.1%) 459 (3.0%) 100 (0.6%) 106 (0.7%) 
≥ 70 2,997 (19.5%) 430 (2.8%) 97 (0.6%) 266 (1.7%) 67 (0.4%) 57 (0.3%) 
Gender 
Female 8,976 (58.5%) 728 (4.7%) 197 (1.3%) 452 (2.9%) 79 (0.5%) 63 (0.4%) 
Male 6,364 (41.5%) 603 (3.9%) 121 (0.8%) 373 (2.4%) 109 (0.7%) 125 (0.8%) 
Indications 
Benign symptoms ** 7,766 (50.6%) 516 (3.3%) 147 (0.9%) 321 (2.1%) 48 (0.3%) 21 (0.1%) 
Alarm symptoms *** 1,691 (11.0%) 190 (1.2%) 67 (0.4%) 109 (0.7%) 14 (0.1%) 28 (0.2%) 















Table 2. Endoscopists and EBR group characteristics for Derivation and Validation 
cohorts (Unit A and Unit B) 
Endo- 
scopist 
EBR EGDs GPC (%)* GD (%) 










Derivation cohort (EGD n=15,340) 
1 22.4 1,700 41 (2.4%) 6 (0.3%) 
Low EBR  
(22.4-
36.7%) 
1.0 - 1.0 - 
2 23.4 470 25 (5.3%) 2 (0.4%) 
3 28.4 264 10 (3.8%) 1 (0.4%) 
4 35.5 2,738 197 (7.2%) 29 (0.5%) 




1.6 1.3-1.9 2.1 1.1-3.9 
6 40.5 1,714 131 (7.6%) 24 (0.6%) 
7 40.9 428 44 (10.3%) 14 (1.2%) 
8 43.2 273 20 (7.3%) 4 (1.1%) 
9 44.1 290 24 (8.3%) 3 (0.7%) 
High EBR  
(43.8-
51.6%) 
2.0 1.7-2.4 2.7 1.5-4.7 
10 46.1 1,682 139 (8.3%) 24 (0.6%) 
11 49.1 422 49 (11.6%) 9 (1.4%) 
12 50.2 1,272 156 (12.3%) 23 (1.4%) 
13 53.0 415 51 (12.3%) 4 (0.5%) 
Very-High 
EBR (51.7 - 
65.8%) 
2.5 2.1-2.9 1.9 1.1-3.4 
14 55.3 517 57 (11.0%) 4 (0.4%) 
15 58.6 278 30 (10.8%) 2 (0.7%) 
16 65.8 2,737 349 (12.8%) 39 (0.8%) 
Validation cohort (EGD n=14,294) 















*- including atrophic gastritis, intestinal metaplasia, low-, indefinite-, and high- grade 
dysplasia 
EBR, endoscopists biopsy rate; EGD, esophagogastroduodenoscopy; GD, gastric 






B 22.4 339 3 (0.9%) 3 (0.9%) (22.0 -
36.7%) C 27.4 3,289 52 (1.6%) 17 (0.5%) 
D 30.4 1,656 47 (2.8%) 26 (1.6%) 
E 30.5 617 16 (2.6%) 4 (0.6%) 
F 35.4 3,689 82 (2.2%) 31 (0.8%) 
G 41.2 1,338 21 (1.6%) 9 (0.7%) Moderate 
EBR (36.8–
43.7%)  
0.8 0.5–1.2 0.9 0.5–1.6 
H 42.1 447 6 (1.3%) 3 (0.7%) 




3.0 2.4–3.7 1.0 0.6–1.6 



















Figure 1. Study flowchart. EGD, Esophagogastroduodenoscopy; EBR, endoscopists 
biopsy rate; GC, gastric cancer. 
Figure 2 . Combined data from Unit A and Unit B showing association between 
endoscopists’ biopsy rate and detection of gastric premalignant conditions (red 
circles) and dysplasia (blue circles). Each circle represents single endoscopists’ 
performance and the diameter of the circle corresponds to the number of 
endoscopies performed by endoscopist. rs- Spearman correlation. 
























































BE – Barrett’s esophagus 
DA – Duodenal adenoma 
EGD - Esophagogastroduodenoscopy 
EBR – Endoscopists’ biopsy rate 
GC – Gastric cancer 
GD – Gastric dysplasia 
GPC – Gastric precancerous condition 
OR – Odds Ratio 
SIN – Squamous intraepithelial neoplasm 
UGI – Upper gastrointestinal tract 
